Haemonetics HAE Impairment of intangible assets
Impairment of intangible assets at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's impairment of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's impairment of intangible assets?
- Haemonetics (HAE) reported impairment of intangible assets of $21.64M in Q1 2026.
- How has Haemonetics's impairment of intangible assets changed year-over-year?
- Haemonetics's impairment of intangible assets increased by 3519.7% year-over-year, from $597.75K to $21.64M.
- What is the long-term trend for Haemonetics's impairment of intangible assets?
- Over 2 years (2024 to 2026), Haemonetics's impairment of intangible assets has grown at a 188.2% compound annual growth rate (CAGR), from $10.42M to $86.55M.
- What does impairment of intangible assets mean?
- This metric represents a non-cash charge recognized when the carrying amount of an intangible asset exceeds its fair value, indicating that the asset's future economic benefit has declined. It often reflects challenges in realizing the projected synergies or market performance originally anticipated at the time of acquisition. High or recurring impairment charges are critical indicators of potential overpayment for assets or deteriorating competitive positioning within specific business segments.